Policy strategies to maximize uptake include inclusion in essential medicines lists, expansion of coverage for non-diabetic HF indications, and integration of SGLT2 inhibitors into bundled payment or value-based care models that reward hospitalization reduction [66,67]. Here, SLC5A2 is linked to hydrops fetalis.